Skip to main content

Peer Review reports

From: The UPMC OPTIMISE-C19 (OPtimizing Treatment and Impact of Monoclonal antIbodieS through Evaluation for COVID-19) trial: a structured summary of a study protocol for an open-label, pragmatic, comparative effectiveness platform trial with response-adaptive randomization

Original Submission
1 May 2021 Submitted Original manuscript
4 May 2021 Reviewed Reviewer Report - Kirsty Loudon
Resubmission - Version 2
Submitted Manuscript version 2
6 May 2021 Editorially accepted
25 May 2021 Article published 10.1186/s13063-021-05316-3

You can find further information about peer review here.

Back to article page